Emerging Tasigna Litigation

 Tasigna Emerging Litigation

Tasigna by Novartis AG

Tasigna (NILOTINIB HYDROCHLORIDE MONOHYDRATE) made by Novartis gained FDA approval in October 2007, New Drug Application (NDA: 022068)

Tasigna is FDA approved for the treatment of accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia  in adult patients resistant to or intolerant to prior therapy.

Unwarned adverse events potentially associated with Tasigna include accelerated atherosclerosis. This life-threatening condition occurs when plaque accumulates in the arteries. As plague builds up in the arteries, a reduction in blood flow can occur, resulting in a large number of secondary conditions which in some cases can lead to death.

How to Learn More About the Emerging Tasigna Litigation

The emerging Tasgina Litigation will be used as a case study in the May 18 – 21, 2018 Mass Tort Nexus, “Four Days to Mass Tort Success Course” to register for the May Course, contact Jenny Levine at jenny@masstortnexus.com or call (954) 520-4494.

For information on the class and to enroll, use this link-“Enroll Here To Attend “Four Days to Mass Tort Success”

Course attendees will receive the benefit of a step by step analysis of the emerging Tasigna Litigation, using these primary metrics:

Mass Tort Nexus Metrics














See endorsements below of some of the top mass tort trial lawyers in the country who’ve attended the Mass Tort Nexus Immersion Course>





The Mass Tort Nexus Classes on Emerging Litigation and Ongoing Mass Torts are considered the premier source in the country to learn about the fundamentals of mass torts and how to enhance your firm practice, increase revenues and manage the related business operations effectively.  Don’t wait for the next class or next year, enroll today and learn what others already have, Mass Torts are where your firm can and will grow its practice.

Share this Post: